PCG Symposium 2026 Brings India’s Complex Therapeutics Ecosystem Together to Address the Billion Dose Challenge
September 29, 2026, | Mumbai
The 2nd edition of the Peptides & Complex Generics Symposium (PCG 2026), hosted by Mumbai Biocluster, an initiative of the Institute of Chemical Technology (ICT), Mumbai, concluded on September 29, 2026, bringing together 400+ stakeholders across the pharmaceutical, biotechnology, academic, regulatory and technology sectors. The two-day programme featured 75+ speakers, 30+ Panel Discussions and 20+ Exhibitors, covering key developments across peptides, complex generics, oligonucleotides, manufacturing, regulation, drug delivery systems and devices, analytical characterization and AI advancements.
Day One Highlights
The opening plenary, “Billion Dose Challenge: Can India Scale Without Compromising Quality?”, brought together leaders from CDSCO, Dr. Reddy’s Laboratories, Novo Nordisk and Bharat Serum Vaccines to discuss the growing demand for peptide and GLP-1 therapeutics and the manufacturing capabilities required to meet it. The session was moderated by Dr. Ratnesh Jain, Founder & Director, Mumbai Biocluster and Convenor, PCG Symposium.
The programme also examined global supply-chain resilience beyond China+1, with a plenary panel moderated by Mr. Salil Kallianpur, Founder & MD, ARKS Knowledge Consulting Pvt. Ltd., featuring Mr. Bharat Shah, MD, S Kant Healthcare Ltd. & National President, IDMA; Mr. Namit Joshi, Chairman, Pharmexcil; Mr. Gunjan Singh, CEO, API Plus, Cohance Lifesciences Ltd.; and Dr. Rohtash Kumar, Head of CDMO, Small & Large Molecules, Syngene International Ltd. The programme further explored peptide synthesis and scale-up, regulatory pathways, drug delivery technologies, and an FDA fireside discussion covering recommendations on product-specific guidance for generic peptides, oral peptides and oligonucleotides.
Day Two Highlights
The second day expanded the focus to oligonucleotide therapeutics, covering manufacturing scale-up, analytical characterization, bioassays, and immunogenicity risk assessment. Discussions also explored next-generation drug delivery and oral peptide delivery, before the scientific programme concluded with “AI Advantage: Turning ML into Faster, Smarter Drug Development,” examining the application of AI and machine learning in accelerating drug development.
Workshops, Exhibition & Research Showcase
PCG 2026 also featured 5 exclusive closed door leaderships roundtables and 3 specialized workshops focused on cost-of-goods reduction for peptide therapeutics, oligonucleotides from molecular design to market, and peptide purification masterclass, bringing participants together for focused technical and practical discussions.
The Molecule to Market Expo brought together technology and solution providers from across the complex therapeutic ecosystem, with an interactive gamification experience running across exhibitor booths. Visitors could scan in, participate in booth-led quizzes, and earn scores tracked through a dedicated gamification portal, with the highest-scoring participant emerging as the winner. The Poster Programme highlighted 20+ research poster presentations spanning peptides, oligonucleotides, novel drug delivery, next-generation therapeutics, analytical technologies, immunogenicity and computational approaches.
PCG 2026 – Connecting Science, Manufacturing & Regulation
PCG 2026 provided a platform for scientists, industry leaders, regulators, policy makers, technology providers, and researchers to exchange perspectives on the development and manufacturing of these increasingly complex therapeutics.
The second edition also expanded the symposium’s scientific scope to include oligonucleotide therapeutics, strengthening the conversation around the technologies, capabilities and collaborations required to take next-generation therapeutics from pilot to scale and volume to value. A pivotal moment was the Leadership Roundtable on Oligonucleotides & ASOs, focusing on scalable purification and regulatory convergence, while highlighting India’s potential in the growing nucleic acid therapeutics CDMO landscape, projected to reach USD 33.86 billion by 2030 at a CAGR of 14.2% from 2025 to 2030.
As the ecosystem continues to evolve, PCG 2027 will carry this conversation forward, bringing together voices shaping what comes next in peptides, oligonucleotides and complex therapeutics.
Science will move forward. The challenges will evolve. And the conversation will continue with PCG 2027.
For more information about the conference and upcoming events, please visit:
